about
Natural Killer Cells for Therapy of LeukemiaImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsMembrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cellsImmunological and Translational Aspects of NK Cell-Based Antitumor ImmunotherapiesUnderstanding of molecular mechanisms in natural killer cell therapyImproving natural killer cell cancer immunotherapyNK cells in therapy of cancerNatural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancerClearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against RhabdomyosarcomaExpansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentratesOpportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseResveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibitionDevelopment of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro.Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.Attribution of NKG2DL to the inhibition of early stage allogeneic tumors in mice.Role of Natural Killer Cells in HIV-Associated Malignancies.Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.Targeting natural killer cells and natural killer T cells in cancer.The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses.Clinical utility of natural killer cells in cancer therapy and transplantation.Clinical grade purification and expansion of natural killer cells.Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.Natural Killer Cell Immunotherapy: From Bench to Bedside
P2860
Q26745906-9D9E4B7F-0AE6-493C-B9BF-8E8AB8BAD7FAQ26765115-14B9B54A-16C4-479B-ADEE-4A13EF081E3BQ27309991-FFB2C6BE-F8B4-494E-AD90-04BF615C9113Q28079180-15B1EA9B-B082-4667-9BE5-15207AEB9715Q28086976-112D3259-F011-4F25-90FF-6F8474871CB9Q28087719-5616E055-3FB6-48C9-AB22-A3211D622324Q28242241-CF56011B-9324-476C-BBCE-2970C9DA430AQ33715830-FA3107AD-8A6B-4387-8D62-C594994865EFQ33781150-489D91CB-73BF-4ED6-B659-AC175B8AEB57Q33785788-2825F5AC-F137-4D85-91C5-3F92914BD2F0Q33905311-BE1D3F27-AFA7-4308-BD26-A902CEB06001Q33922539-02999C61-2602-4535-8CA3-DA664BC6A9E7Q34307792-FA276032-7271-49E7-8964-8C17F798B828Q34571639-76B0FDDE-A5A4-4527-8EF4-089A01B20ADDQ34618454-D27AA348-E411-4663-81BD-50019770DA93Q35177618-A880E08E-0562-4559-9085-973A9906CC56Q35600095-3C2039B6-3C59-4367-8838-67C56951E228Q35752181-F23667BC-68F2-4F8D-BC2C-FEA912ED8015Q35963440-779B0BE9-8447-4F73-89DE-F6F86E1B7AF0Q36187369-A7FC1B0D-1EF3-41D8-BFEE-C152708A43AAQ36478280-52450867-700C-442A-AD1C-603FB73F575DQ36712059-685C5807-A38C-4CFF-B070-C8D8F394C804Q36856792-71C8DF6F-46F2-4DC2-950F-018E88C225D1Q36999109-1B19C6CA-4D9D-4926-8341-70990E0FFFF7Q37261189-CCD1ECBD-3965-4682-911D-B21CF43F8327Q37565475-FBB7C0F2-B370-404B-864C-4BD4AEC23CF1Q37579561-6B05F80E-95AD-4189-BD9C-3D52A3785765Q37589671-C0AAD14A-8465-4B29-85AF-DC6DB77D3233Q37637949-B4121605-7F1B-4B77-9183-DC79A52B3AEFQ37696132-DD7686A3-4C50-46C4-BEF2-7FA4D340297BQ37712593-173862BC-53C8-4E1C-8AAE-84DFA155AA74Q37905034-624CA479-149F-4A05-9F48-53EFE79ACAF8Q37993738-26C2FC49-ACAB-40B8-B05D-1C23256ACF46Q37995950-6C99A2B1-2CA0-4D14-8A8B-400E1B436BA1Q38073762-4AA97570-3590-4FC3-B4EA-83AC3CAE8CA9Q38195120-F86818DC-48A4-4F7A-A3A2-3A93912B3958Q38221228-88093F01-766B-4C82-BF0F-1C6D21CD2520Q38233046-2AC2146D-AA0C-4D78-9C68-C6890A5D81BBQ38513534-F1C5E054-A97E-4A52-8E7A-250A3448C1B0Q38531958-36DCFA3D-1C7A-4CEE-AEB1-C3F1C7F5C51F
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Allogeneic natural killer cells for refractory lymphoma
@ast
Allogeneic natural killer cells for refractory lymphoma
@en
type
label
Allogeneic natural killer cells for refractory lymphoma
@ast
Allogeneic natural killer cells for refractory lymphoma
@en
prefLabel
Allogeneic natural killer cells for refractory lymphoma
@ast
Allogeneic natural killer cells for refractory lymphoma
@en
P2093
P2860
P1476
Allogeneic natural killer cells for refractory lymphoma
@en
P2093
Bruce R Lindgren
Daniel Weisdorf
David H McKenna
Jeffrey S Miller
Julie Curtsinger
Linda J Burns
Sarah Cooley
Veronika Bachanova
P2860
P2888
P304
P356
10.1007/S00262-010-0896-Z
P577
2010-08-03T00:00:00Z
P6179
1015126438